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Chronic kidney disease (CKD) is associated with an increased
risk of cardiovascular morbidity and mortality. Arterial
stiffness and remodeling have been well documented in
patients with end-stage renal disease, but little is known
about arterial phenotype in CKD patients with moderate
reduction in glomerular filtration rate (GFR). In total,
95 patients (58715 years, mean7s.d.) with CKD and
GFR measured by renal clearance of
51Cr-ethylenediaminetetraacetate were compared to 121
hypertensive patients without CKD (59711 years), and 57
normotensive subjects (5676 years). Common carotid artery
diameter, intima–media thickness (IMT), distensibility, and
Young’s elastic modulus were noninvasively determined with
a high-definition echotracking system. Patients with CKD had
a significantly larger carotid internal diameter than in
hypertensives and normotensives (6.3271.05, 5.8470.74,
and 5.5070.64 m 103, respectively; Po0.001), resulting in
25% and 11% increases in circumferential wall stress,
respectively, since no significant difference in IMT was
observed. Carotid distensibility and elastic modulus did not
significantly differ between CKD and hypertensives;
normotensives had significantly higher distensibility and
lower elastic modulus than CKD and hypertensive patients.
Carotid-femoral pulse wave velocity was significantly higher
in CKD patients than in hypertensives and normotensives.
In multivariate analyses either involving the entire
population or restricted to CKD patients, GFR was
independently and strongly related to carotid diameter and
elastic modulus. Arterial enlargement and increased arterial
stiffness occur in parallel with the decline in renal function in
patients with mild-to-moderate CKD.
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Chronic kidney disease (CKD) is a worldwide public health
problem. Epidemiological studies have shown a rising
prevalence and incidence of CKD in all Western countries.1
Evolution towards end-stage renal disease exposes patients to
a well-known increased risk of cardiovascular morbidity and
mortality.2 CKD has also been recently individualized as an
independent risk factor for cardiovascular disease, propor-
tionally with the decline in glomerular filtration rate (GFR),
indirectly estimated either from the Modification of Diet in
Renal Disease (MDRD) or Cockcroft formula.2–4
Subclinical markers of arterial disease include aortic
stiffness and carotid intima–media thickness (IMT). Aortic
stiffness has shown an independent predictive value for total
and cardiovascular mortality, coronary heart disease, and
fatal stroke, in essential hypertensive patients,5–7 end-stage
renal disease,8,9 and diabetic patients.10 The predictive values
of aortic and carotid stiffness for cardiovascular events were
the strongest in patients with end-stage renal disease
(ESRD).8,9 Carotid IMT has shown an independent pre-
dictive value for coronary heart disease and stroke in a
general population,11,12 and for cardiovascular mortality in
ESRD patients.13
Although arterial phenotype has been well documented in
ESRD,14–16 available data about arterial wall properties in
patients with mild-to-moderate CKD, not yet on dialysis
therapy,17–19 are hampered by indirect estimation of GFR.
Pathogenic mechanisms of arterial disease in CKD include
various mechanisms such as endothelial dysfunction,20
leading to vasoconstriction and arterial growth, oxidant
stress,21,22 dysfunction of nitric oxide metabolism,23 inflam-
mation,24 glycoxidation,25 and vascular calcification.26 As
these mechanisms are also involved in the progression of
kidney disease,22,27 we hypothesized that the reduction in
GFR would be related to the extent of arterial stiffness and
thickness.
We took advantage of the high precision and repeatability
of the measurements of GFR by 51Cr-ethylenediaminetetra-
acetate (EDTA) and arterial parameters by echotracking
techniques to (1) characterize the functional and structural
properties of large arteries in patients with CKD, by
comparison with patients with normal renal function having
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either hypertension or not, and (2) put in evidence the
relationship between GFR reduction and the extent of arterial
damage. The present study is the cross-sectional analysis of
patients with CKD entering a 3-year longitudinal follow up of
renal function together with large artery properties, the REN-
ART (RENal dysfunction and large ARTeries properties: a
longitudinal study).
RESULTS
The characteristics of the populations are presented in
Table 1. CKD, hypertensive, and normotensive subjects were
comparable for age and sex ratio. In addition, hypertensives
and CKD patients had no significant difference in brachial
systolic blood pressure (SBP), diastolic blood pressure (DBP),
mean blood pressure (MBP), and PP. CKD patients had more
often diabetes and hypercholesterolemia than hypertensive
patients. According to the recommendations in use, CKD
patients were more intensively treated with antihypertensive
drugs (mostly blockers of the renin–angiotensin–aldosterone
system) and statins. Blood cholesterol was subsequently
significantly lower in CKD patients.
Arterial geometry
In CKD patients, carotid internal diameter, normalized to
body surface area (BSA), was 9 and 12% higher than in
hypertensive and normotensive subjects, respectively (analy-
sis of variance (ANOVA), Po0.001) (Table 2). Carotid IMT
was not significantly different between hypertensive, CKD,
and normotensive subjects. In CKD patients, carotid wall
cross-sectional area (WCSA) was 3 and 16% higher than in
hypertensive and normotensive subjects, respectively (ANOVA,
Po0.001). According to a higher carotid diameter and a
similar IMT, wall-to-lumen ratio was significantly lower in
CKD than in hypertensives (Po0.05). In CKD patients,
carotid circumferential wall stress was 11 and 25% higher
than in hypertensive and normotensive subjects, respectively
(ANOVA, Po0.001).
In multivariate analysis involving the entire population
(Table 3), carotid PP, age, and GFR (MDRD) were all
independently related to carotid internal diameter, and GFR
explained 9% of the variance. In CKD patients, a significant,
negative, and independent relationship between GFR (51Cr-
EDTA) and carotid internal diameter was found (Table 4 and
Figure 1): the lower the GFR, the higher the diameter.
Table 1 | Characteristics of studied populations
P-value
Parameters
Chronic kidney
disease (CKD)
Hypertensives
(HT)
Normotensives
(NT) ANOVA CKD vs HT CKD vs NT HT vs NT
N 95 121 57
Age (years) 58.4714.9 58.8710.6 56.376.1 0.38 NS NS NS
Sex ratio (% men) 74 59 59 0.07 NS NS NS
BSA (m2) 1.870.2 1.870.2 1.870.2 0.22 NS NS NS
BMI (kg/m2) 25.674.5 25.573.2 23.572.8 o0.001 NS o0.05 o0.05
Smoking (%) 13 9 17.5 0.15 NS NS NS
Hypertension (%) 89 100 0 o0.001 o0.05 o0.05 o0.05
Diabetes (%) 11 5 0 o0.001 o0.05 o0.05 o0.05
Hypercholesterolemia (%) 71 28 23 o0.001 o0.05 o0.05 o0.05
GFR MDRD (ml/min/1.73 m2) 31714 86724 92.2721.2 o0.001 o0.05 o0.05 NS
GFR 51Cr-EDTA (ml/min/1.73 m2) 36716 — — o0.001 o0.05 — —
Glycemia (mmol/l) 5.571.2 5.670.2 5.070.7 0.05 NS o0.05 o0.05
Cholesterolemia (mmol/l) 4.670.9 5.571.0 5.671.0 o0.001 o0.05 o0.05 NS
Triglyceridemia (mmol/l) 1.570.9 1.572.3 1.2170.8 0.54 NS NS NS
Cholesterol HDL (mmol/l) 1.170.3 1.470.5 1.470.3 o0.001 o0.05 o0.05 NS
Cholesterol LDL (mmol/l) 2.970.9 3.971.2 2.6370.8 o0.001 o0.05 NS o0.05
Antihypertensive therapy (%) 94 87 0
No. of antihypertensive drugs 2.4971.24 1.6871.23 — o0.001 o0.05 — —
Patients with RAS blockers (%) 84 69 — o0.001 o0.05 — —
Patients with statins (%) 60 15 — o0.001 o0.05 o0.05 NS
Patients with calcium-channel blockers (%) 48 34 — o0.001 o0.05 — —
Brachial blood pressure
Systolic BP (mmHg) 134720 134719 117712 o0.001 NS o0.05 o0.05
Mean BP (mmHg) 94711 96712 8678 o0.001 NS o0.05 o0.05
Diastolic BP (mmHg) 7479 77710 7177 o0.001 NS o0.05 o0.05
Pulse pressure (mmHg) 60717 57714 4679 o0.001 NS o0.05 o0.05
Heart rate (bpm) 64710 65710 6679 0.5 NS NS NS
Carotid blood pressure
Systolic BP (mmHg) 124720 128722 109714 o0.001 NS o0.05 o0.05
Diastolic BP (mmHg) 73712 77711 7178 o0.001 o0.05 NS o0.05
Pulse pressure (mmHg) 50716 50717 4679 o0.001 NS o0.05 o0.05
ANOVA, analysis of variance; BMI, body mass index; BP, blood pressure; BSA, body surface area; GFR, glomerular filtration rate; HDL, high density lipoprotein; LDL, low density
lipoprotein; RAS renin–angiotensin system.
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In multivariate analysis involving the entire popu-
lation (Table 3), MBP, age, and GFR (MDRD) were all
independently related to circumferential wall stress, and
GFR explained 4% of the variance. In CKD patients, a
significant, negative, and independent relationship bet-
ween GFR (51Cr-EDTA) and circumferential wall stress was
found, GFR explaining 7% of the variance (Table 4 and
Figure 1).
Table 2 | Carotid artery and aortic parameters in patients with chronic kidney disease and in control subjects
P-value
Parameters
Chronic kidney
disease (CKD)
Hypertensives
(HT)
Normotensives
(NT) ANOVA CKD vs HT1 CKD vs NT1 HT vs NT1
Carotid artery
Internal diastolic diameter (m 103) 6.3271.05 5.8470.74 5.5070.64 o0.001 o0.05 o0.05 NS
Internal diastolic diameter (m 103/1.73 m2) 6.0370.95 5.5270.68 5.3870.69 o0.001 o0.05 o0.05 NS
Intima-media thickness (m 106) 7277157 7567137 714796 NS NS NS NS
Wall cross-sectional area (m2 106) 16.274.9 15.773.7 13.972.7 o0.001 NS o0.05 o0.05
Thickness/radius ratio (h/r) 0.2370.05 0.2670.06 0.2670.05 o0.001 o0.05 o0.05 NS
Circumferential wall stress (kPa) 56.3715.2 50.8713.1 45.1710.6 o0.001 o0.05 o0.05 o0.05
CS distensibility (kPa1 103) 24.0714.1 21.2710.3 29.4713.2 o0.001 NS o0.05 o0.05
CS compliance (m2 kPa1 107) 7.073.0 5.672.7 7.070.3 o0.001 o0.05 NS o0.05
Young’s Elastic modulus (kPa 103) 0.51770.325 0.49770.283 0.33070.147 o0.001 NS o0.05 o0.05
Carotid pulse pressure (mmHg) 50716 50717 4679 o0.001 NS o0.05 o0.05
Augmentation index (%) 32713 35714 35713 NS NS NS NS
Aorta
Carotid-femoral pulse wave velocity (m/s) 11.372.7 10.672.02 9.571.07 o0.001 o0.05 o0.05 o0.05
1GLM-ANOVA completed by Bonferonni post-hoc tests.
Table 3 | Multivariate relationships of aortic and carotid parameters in the three groups of patients considered as a whole
Parameters In/Out R2 increment % Beta coeff. Lower CI Upper CI P
Dependent variable: carotid diameter (BSA adjusted)
MBP IN 3 0.01 0.002 0.017 0.001
Age IN 10 0.018 0.011 0.024 0.0001
Glomerular filtration rate (MDRD) IN 9 0.006 0.008 0.004 0.0001
Heart rate OUT — — — — —
Carotid pulse pressure OUT — — — — —
R2=0.25
Sqrt(MSE)=0.57
Dependent variable: carotid circumferential wall stress
Carotid pulse pressure IN 4 0.16 0.07 0.25 0.0001
Age IN 6 0.27 0.4 0.14 0.0001
Glomerular filtration rate (MDRD) IN 4 0.08 0.125 0.04 0.0001
Heart rate OUT — — — — —
R2=0.12
Sqrt(MSE)=10.9
Dependent variabe: carotid Young’s elastic modulus
Mean BP IN 25 8.4 6.8 9.9 0.0001
Age IN 13 6.2 4.7 7.8 0.0001
Glomerular filtration rate (MDRD) IN 2 0.9 1.45 0.35 0.001
Heart rate OUT — — — — —
R2=0.44
Sqrt(MSE)=135.5
Dependent variable: Carotid-femoral pulse wave velocity
Sex IN 1 0.31 0.62 0.001 0.05
Mean BP IN 17 0.06 0.05 0.08 0.0001
Heart rate IN 2 0.03 0.01 0.04 0.0001
Age IN 26 0.8 0.07 0.09 0.0001
Glomerular filtration rate (MDRD) IN 2 0.007 0.012 0.003 0.001
R2=0.52
Sqrt(MSE)=1.135
MBP, mean blood pressure; CI, consicence interval, BP, blood pressure.
352 Kidney International (2006) 69, 350–357
o r i g i n a l a r t i c l e M Briet et al.: Large arteries in chronic kidney disease
Elastic properties of the common carotid artery and aorta
Carotid distensibility was significantly lower in CKD than in
normotensive subjects (CKD vs normotensives, 18%,
Po0.001), but did not differ between CKD and hyperten-
sives. Carotid Young’s elastic modulus (Einc) did not differ
between CKD and hypertensive patients, but was significantly
higher in CKD than in normotensive subjects (þ 57%,
Po0.001). Carotid compliance was significantly higher in
CKD patients than in hypertensive patients (CKD vs
hypertensive patients, þ 25%, Po0.001) according to an
increase in internal diameter. In multivariate analysis
involving the entire population (Table 3), MBP, age, and
GFR (MDRD) were all independently related to carotid
elastic modulus, with age explaining 13% of the variance and
GFR 2%. In CKD patients, a significant, negative, and
independent relationship between GFR (51Cr-EDTA) and
carotid elastic modulus was confirmed (Table 4 and Figure 1),
with GFR explaining 3% of the variance. On the contrary,
carotid elastic modulus was the only significant determinant
of GFR (51Cr-EDTA), explaining 12% of variance.
In CKD patients, aortic stiffness, assessed by carotid-
femoral pulse wave velocity (CF-PWV), was 7 and 19%
higher than in hypertensive and normotensive subjects,
respectively (ANOVA, Po0.001) (Table 2). In multivariate
analysis involving the entire population (Table 3), sex, MBP,
HR, age, and GFR (MDRD) were all independently related to
aortic stiffness, with age explaining 26% of the variance and
GFR 2%. We did not find significant and independent
relationship between GFR (51Cr-EDTA) and CF-PWV in the
population of CKD patients (Table 4).
DISCUSSION
The present study is the first one to report relationships
between GFR, measured with the gold standard 51Cr-EDTA
technique, and arterial parameters, in mild-to-moderate
CKD patients. The three major findings are the following.
Compared to hypertensive patients without CKD, patients
with CKD had an outward remodeling of the carotid artery,
with enlargement of lumen diameter predominating over
carotid wall thickening and stiffening. Estimated GFR
(MDRD) was independently related to arterial diameter,
circumferential wall stress, and aortic and carotid stiffness in
the whole population. Compared to age and blood pressure
(BP), GFR had a similar independent influence on arterial
enlargement, but a weaker influence on arterial stiffness. In
addition, and most importantly, GFR measured with 51Cr-
EDTA renal clearance is a strong and independent determi-
nant of arterial dilatation and stiffening within CKD patients.
Carotid stiffness was the only determinant of GFR (51Cr-
EDTA), accounting for 12% of variance.
Interpretation of findings
Compared to hypertensive patients without CKD, the
remodeling of the carotid artery in CKD patients involves
Table 4 | Multivariate relationships of aortic and carotid parameters in patients with chronic kidney disease
Parameters In/Out R2 increment % Beta coeff. Lower CI Upper CI P
Dependent variable: CCA diameter (BSA adjusted)
Age IN 16 0.02 0.012 0.029 0.0001
Heart rate IN 5 0.02 0.03 0.0004 0.03
Calcium antagonist use IN 3 0.29 0.03 0.56 0.03
Glomerular filtration rate (51Cr-EDTA) IN 3 0.009 0.02 0.001 0.03
R2=0.44
Sqrt(MSE)=0.54
Dependent variable: Circumferential wall stress
Calcium-channel blockers IN 6 7.8 2.1 13.4 0.01
Cholesterol HDL IN 4 12.7 21.6 3.9 0.03
Glomerular filtration rate (51Cr-EDTA) IN 7 0.23 0.39 0.07 0.008
R2=0.21
Sqrt(MSE)=13.9
Dependent variabe: Einc
Mean blood pressure IN 19 10.1 6.7 13.5 0.0001
Age IN 18 6.7 4 9.3 0.0001
Glomerular filtration rate (51Cr-EDTA) IN 3 2.5 4.7 0.2 0.03
Diuretic use OUT — — — — —
R2=0.58
Sqrt(MSE)=160
Dependent variable: CF-PWV
MBP IN 15 0.09 0.06 0.12 0.0001
Age IN 33 0.09 0.07 0.12 0.0001
Glomerular filtration rate (51Cr-EDTA) OUT — — — — —
R2=0.63
Sqrt(MSE)=1.39
CCA, common carotid artery; BSA, body surface area; 57Cr-EDTA, 51Cr-ethylenediaminetetraacetate; MBP, mean blood pressure; CF-PWV, carotid femoral pulse wave velocity.
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mainly an enlargement of lumen diameter predominating
over carotid wall thickening, in parallel with stiffening.
Although arterial dilatation has been shown in patients with
ESRD,16 to our knowledge, this is the first report in patients
with mild-to-moderate CKD, not yet on dialysis therapy.
Several arguments suggest that arterial dilatation is
probably due to the inability of elastic fibers to sustain
physiological pulsatile stress, by analogy with aging.28,29 The
progressive disorganization of elastic fibers with aging
(thinning and fragmentation) is generally considered as a
sign of mechanical failure and fatigue of biomaterial. In
addition, qualitative alterations of elastin fibers (calcification,
glycoxidation, and lipid peroxidation)30 and quantitative
alterations (decrease in elastin content)31 have been shown in
experimental CKD models. The observed negative relation-
ship between GFR and carotid lumen diameter is consistent
with an accelerated aging of the arterial wall in CKD
patients.32 Many other factors that could potentially explain
carotid dilatation had no independent influence, and GFR
remained significant in multivariate analysis either in the
entire population or in CKD patients only. After age, BP, and
GFR, calcium channel blockers, known to dilate carotid
artery in hypertensive patients,33 were independently asso-
ciated with carotid dilatation in CKD patients (Table 4).
Volume overload may have influenced also the arterial
diameter; however, no significant correlation was found
between extracellular volume (measured by the volume of
distribution of 51Cr-EDTA) and arterial diameter within the
population of CKD patients (data not shown). Hematocrit
and hemoglobin were both correlated with internal diameter,
but were not independently correlated after inclusion of GFR
in the model, further indicating that dilatation and increased
stress were not related to chronic increase in flow due to
hypervolemia or anemia.
It is assumed that thickening is an adaptative response of
the arterial wall to increased BP or dilatation, to normalize
circumferential wall stress. In CKD, increased lumen
diameter was not compensated by wall thickening, leading
to increased circumferential wall stress. This suggests a defect
in mechanotransduction, that is, the control of smooth
muscle cell growth and migration, and production of
extracellular matrix in response to diameter enlargement.
The link between reduced renal function and this process is
reinforced by the gradual increase in circumferential wall
stress with a decrease in GFR (51Cr-EDTA) in CKD patients
(Figure 1), with GFR explaining 7% of the variance of
circumferential wall stress (Table 4).
Aortic stiffness was significantly higher in CKD than in
hypertensives, despite similar age and BP in both groups.
Since BP levels, including central pulse pressure, are
comparable in CKD and hypertensive patients, this exaggerated
response probably involves a mechanism different from the
passive loading of arterial wall stiff components by increased
BP. An increase in aortic stiffness in hemodialysis patients has
been consistently demonstrated by various investiga-
tors3,9,14,16,34–37 and partially attributed to an increase in
the calcium content of the arterial wall.38,39 Arterial
calcification has also been demonstrated in patients with
moderate chronic renal failure.40 Calcium, iron metabolisms,
and microinflammation had no independent effect on
arterial stiffening or dilatation. Other mechanisms could be
involved, including qualitative changes in arterial wall during
CKD (advanced glycation end products, lipid peroxidation,
and elastin fragmentation)30 and/or quantitative changes
(increased amount of wall material, hyperplasia of smooth
muscle cell, increased collagen content, and reduced amount
of elastic fibers).31 Carotid stiffness was not higher in CKD
than in hypertensives. This suggests an exaggerated sensitivity
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Figure 1 | Box plots of CCA internal diameter, circumferential wall
stress, and Young’s elastic modulus for patients with CKD, and
51Cr-EDTA GFR as the classification variable. Boxes represent
interquartile range (IQR, i.e. 50% of the distribution); the horizontal
bar is the median; upper whisker represents the 75th percentileþ 1.5
IQR; lower whisker 25th percentile1.5 IQR.
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of the aorta to stiffening in CKD; however, the fact that GFR
reduction was strongly associated with carotid stiffness in
CKD shows that renal function per se has adverse influence
on arterial stiffness. Increased stiffness in CKD patients was
not accompanied by increased pulse pressure. This could be
explained by the more intensive treatments with renin–
angiotensin–aldosterone antagonists and statin therapy,
correcting BP with more marginal effect on stiffness, as
already observed in ESRD patients.41
Our results, showing that GFR was significantly and
independently associated with carotid and aortic stiffness, are
consistent with those of previous studies in CKD patients
without ESRD,17–19 which used an indirect estimation of
GFR known to have a residual influence of age and body size.
The present study demonstrates a gradual alteration of
arterial function with reduced GFR, independent of age and
other confounders. Moreover, we provide quantitative
information through the percentage of explained variance
(Tables 3 and 4). Multivariate analyses, either in the entire
population or in CKD patients only, showed that GFR
explained 2–3% of the variance of carotid elastic modulus or
aortic PWV. When assessed in the reversed way, carotid
stiffness was the only significant determinant of GFR (51Cr-
EDTA), explaining 12% of its variance. GFR had thus a
weaker independent influence on arterial stiffness than age
and BP (which explained 15–33% of the variance of carotid
elastic modulus or aortic PWV), but arterial stiffness was
strongly associated with altered renal function. The interplay
of GFR with arterial stiffness in CKD was undetected in
previous studies.17–19
Methodological features and limitations of the study
The present study has several strengths. First, because age, BP,
and gender are important determinants of arterial stiffness
and thickness, we compared CKD patients to hypertensive
and normotensive patients of similar age and sex ratio, and to
hypertensive patients of similar BP. Second, this study is the
first to combine two gold standard methods: an echotracking
apparatus for measuring arterial parameters in the entire
population, as published previously,28,42,43,29 and 51Cr-EDTA
technique for measuring GFR in CKD patients. Indeed, the
indirect estimate of renal function through creatinine
measurement affords limited information because it is
affected by factors other than creatinine filtration, such as
muscular mass and extrarenal elimination. Formulae includ-
ing anthropometric parameters, such as the Cockcroft and
Gault or the MDRD formula,44 allow GFR estimation but
they still lack precision.45 Moreover, the inclusion of age in
the calculation of estimated GFR hampers the interpretation
of GFR’s influence on parameters themselves strongly
dependent on age (such as CF-PWV). Renal clearance of
EDTA has been shown to be identical to renal clearance of
inulin46 and is currently one of the gold standard methods
for the measurement of GFR. As the administration of
radioisotopes could not be performed in healthy subjects,
even in hypertensives with normal creatinine levels, we used
the MDRD formula to relate GFR to arterial parameters in
the entire population.
The present study has some limitations. First, kidney
disease underlying reduced GFR was of miscellaneous origin,
as described below. In multivariate analysis, we checked that
the origin of CKD was not retained as an independent
determinant of arterial parameters. Second, these patients
were cared about according to the Kidney Disease Outcomes
Quality Initiative (K-DOQI) and Agence Nationale pour
l’Accre´ditation des Etablissements de Sante´ (ANAES) re-
commendations, and received multiple-drug therapy aiming
at reducing their cardiovascular risk factors. This high level of
treatment made it difficult to find a population matched for
all the characteristics of the CKD patients. Thus, we chose to
match CKD patients with hypertensive patients without CKD
for BP and treatment, and to normotensive control subjects.
This matching process may explain the absence of difference
for IMT between groups.
Conclusions and perspectives
This cross-sectional study shows that arterial enlargement,
increased arterial stiffness, and increased circumferential wall
stress occur in parallel with the decline of GFR in patients
with mild-to-moderate CKD. It would be interesting to
correlate baseline arterial damage (notably aortic stiffness
and carotid diameter/circumferential stress) with accelerated
degradation of renal function. This question will be
addressed in the ongoing 3-year longitudinal follow up of a
larger cohort during the REN-ART study.
MATERIALS AND METHODS
A total of 273 patients and subjects were included in the present
study. On the basis of reduced estimated GFR (GFR estimated with
MDRD formula as p60 ml/min/1.73 m2), a group of 95 CKD
patients referred to the nephrology vascular medicine unit of
Georges Pompidou Hospital was recruited. The underlying diseases
were glomerulopathy (21%), chronic interstitial nephritis (22%),
hypertensive nephropathy (28%), and unknown (28%). In all, 95
patients had measurements of GFR directly through 51Cr-EDTA
clearance and arterial parameters, as described below. Besides GFR
determination, cardiovascular risk factors were evaluated and
biological parameters measured, according to the recommendations
of the American and European clinical practice guidelines –
K-DOQI (http://www.kidney.org/professionals/kdoqi/guidelines.cfm)
and ANAES (http://www.anaes.fr/), respectively.
Control groups were composed of 121 patients with essential
hypertension and no reduction in GFR, consulting at the
hypertension clinic of our institution, and 89 normal subjects
recruited among staff members and families. They beneficiated from
arterial measurements, standardized questionnaires for cardiovas-
cular risk factors, and standard biology, including plasma creatinine.
The protocol was approved by the local ethics committee, and all
patients gave written informed consent.
GFR measurements
In the entire population, the simplified MDRD equation (GFR
(ml/min/1.73 m2)¼ 186 (serum Cr (mg/dl))1.154 (age)0.203
(0.742 if female) (1.212 if black))44 was used to estimate GFR. In
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patients with CKD, renal clearance of 51Cr-EDTA was determined as
described previously.45 Briefly, 3.5 MBq of 51Cr-EDTA (Amersham
Health, SA, Pantin, France) was injected intravenously as a single
bolus. After allowing 1 h for distribution of the tracer in the
extracellular fluid, average renal 51Cr-EDTA clearance was deter-
mined on five consecutive 30-min clearance periods. In our hands,
the coefficients of variation of renal clearance of 51Cr-EDTA and
plasma clearance of 51Cr-EDTA were 5.373.7%.
Arterial parameters
All patients and subjects were studied in a quiet room with a
controlled temperature of 22711C as described previously.28,42 BP
was monitored with an oscillometric method (Dinamap model 845,
Critikon). Aortic stiffness was estimated by CF-PWV measured
along the descending thoraco-abdominal aorta by the foot-to-foot
velocity method (Complior, Artech Medical, Pantin, France), as
published previously and validated.47
End-diastolic internal diameter, stroke change in diameter, and
IMT were measured on the right common carotid artery (CCA) with
a high-precision echotracking device (Wall Track System),48 as
described previously and validated.28,42,43,29 End-diastolic internal
diameter was normalized to BSA in order to take into account
anthropometric variation.
Circumferential wall stress was calculated using the Lame´
equation,43 with sy (kPa)¼ (MBP Dm)/2IMTm (where MDm and
IMTm are the mean values of internal diameter and wall thickness
during the cardiac cycle).
Right CCA pressure waveform was recorded noninvasively by
aplanation tonometry, using the Sphygmocor device (AtCor
Medical, Sydney, Australia), as described previously and validated,29
and local carotid artery pulse pressure was used for further
calculations.
Carotid distensibility was determined from the systolic–diastolic
variations in arterial cross-sectional area (DA) and local pulse
pressure (DP) as described previously,42 assuming the lumen to be
circular. Cross-sectional distensibility coefficient (DC) was calcu-
lated as DC¼DA/ADP. Cross-sectional compliance coefficient (CC)
was calculated as CC¼DA/DP. Incremental Young’s elastic modulus
(Einc) was calculated as described previously:
42 Einc¼ [3(1þ
A/WCSA)]/DC, where WCSA is the mean WCSA.
Statistical analysis
Statistics were performed using NCSS 2004 software (Gerry Hintze,
Kaysville, UT, USA). Data are expressed as mean7s.d. Between-
group comparisons for quantitative variables were performed using
GLM-ANOVA, completed by Bonferonni post hoc tests, corrected for
multiple comparisons. w2 test was used for discrete variables.
Multivariate robust regressions with stepwise selection of variables
were performed to determine the relationship between arterial
parameters and GFR, as described previously.28,29
In order to sort out the contribution of the numerous redundant
variables recorded (for instance, body mass index (BMI) and weight
expressing different aspects of obesity, or C-reactive protein (CRP)
and fibrinogen expressing different aspects of inflammation), we
performed clustered selection of variables, each cluster correspond-
ing to a given pathophysiological domain. Clusters were constituted
as follows: morphometric (sex, height, weight, BMI, BSA), blood
pressure (MBP, Pulse pressure, augmentation index), lipids (total
cholesterol, high-density lipoprotein cholesterol, low-density lipo-
protein cholesterol, triglycerides), blood (hematocrit, hemoglobin,
white blood cells), inflammation (fibrinogen, CRP), mineral
metabolism (calcium, phosphorus, parathyroid hormone (PTH)),
and treatment (calcium channel blockers, angiotensin-converting
enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB),
diuretics). Within each cluster, variables were included in a
competitive manner in multivariate models. If covariance was too
high within clusters, the variable having the highest univariate
signification level was retained. In the second step, variables retained
in separate clusters were included in the first multivariate model.
Then, age was introduced in the second model, and finally GFR was
introduced in the third model (presented in Tables 3 and 4).
ACKNOWLEDGMENTS
This study was funded by the French Ministry of Health, De´le´gation
a` la Recherche Clinique, Assistance Publique-Hoˆpitaux de Paris,
Programme hospitalier de Recherche Clinique, Grant AOM 03023
P030439.
REFERENCES
1. USRDS (The United States Renal Data System). Am J Kidney Dis 2003; 42:
1–230.
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of
death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:
1296–1305.
3. Mann JF, Gerstein HC, Yi QL et al. Development of renal disease in people
at high cardiovascular risk: results of the HOPE randomized study. J Am
Soc Nephrol 2003; 14: 641–647.
4. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration
and risk of cardiovascular disease: a possible marker for increased risk of
stroke. Stroke 1997; 28: 557–563.
5. Boutouyrie P, Tropeano AI, Asmar R et al. Aortic stiffness is an
independent predictor of primary coronary events in hypertensive
patients: a longitudinal study. Hypertension 2002; 39: 10–15.
6. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent
predictor of all-cause and cardiovascular mortality in hypertensive
patients. Hypertension 2001; 37: 1236–1241.
7. Laurent S, Katsahian S, Fassot C et al. Aortic stiffness is an independent
predictor of fatal stroke in essential hypertension. Stroke 2003; 34:
1203–1206.
8. Blacher J, Pannier B, Guerin AP et al. Carotid arterial stiffness as a
predictor of cardiovascular and all-cause mortality in end-stage renal
disease. Hypertension 1998; 32: 570–574.
9. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival
in end-stage renal disease. Circulation 1999; 99: 2434–2439.
10. Cruickshank K, Riste L, Anderson SG et al. Aortic pulse-wave velocity
and its relationship to mortality in diabetes and glucose intolerance:
an integrated index of vascular function? Circulation 2002; 106:
2085–2090.
11. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima–media
thickness and risk of stroke and myocardial infarction: the Rotterdam
Study. Circulation 1997; 96: 1432–1437.
12. Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial
intima–media thickness in predicting clinical coronary events. Ann Intern
Med 1998; 128: 262–269.
13. Benedetto FA, Mallamaci F, Tripepi G et al. Prognostic value of
ultrasonographic measurement of carotid intima media thickness in
dialysis patients. J Am Soc Nephrol 2001; 12: 2458–2464.
14. Barenbrock M, Spieker C, Laske V et al. Studies of the vessel wall
properties in hemodialysis patients. Kidney Int 1994; 45: 1397–1400.
15. London GM, Marchais SJ, Safar ME et al. Aortic and large artery
compliance in end-stage renal failure. Kidney Int 1990; 37: 137–142.
16. London GM, Guerin AP, Marchais SJ et al. Cardiac and arterial interactions
in end-stage renal disease. Kidney Int 1996; 50: 600–608.
17. Mourad JJ, Pannier B, Blacher J et al. Creatinine clearance, pulse wave
velocity, carotid compliance and essential hypertension. Kidney Int 2001;
59: 1834–1841.
18. Wang MC, Tsai WC, Chen JY et al. Stepwise increase in arterial stiffness
corresponding with the stages of chronic kidney disease. Am J Kidney Dis
2005; 45: 494–501.
19. Konings CJ, Dammers R, Rensma PL et al. Arterial wall properties in
patients with renal failure. Am J Kidney Dis 2002; 39: 1206–1212.
356 Kidney International (2006) 69, 350–357
o r i g i n a l a r t i c l e M Briet et al.: Large arteries in chronic kidney disease
20. Morris ST, McMurray JJ, Rodger RS et al. Impaired
endothelium-dependent vasodilatation in uraemia. Nephrol Dial
Transplant 2000; 15: 1194–1200.
21. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases:
the role of oxidant stress. Circ Res 2000; 87: 840–844.
22. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and
progression of chronic renal failure. Semin Nephrol 2004; 24: 354–365.
23. Klahr S. The role of nitric oxide in hypertension and renal disease
progression. Nephrol Dial Transplant 2001; 16(Suppl 1): 60–62.
24. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of
cardiovascular disease in patients with end-stage renal disease. Nephrol
Dial Transplant 2004; 19(Suppl 5): V67–V72.
25. Peppa M, Uribarri J, Cai W et al. Glycoxidation and inflammation in renal
failure patients. Am J Kidney Dis 2004; 43: 690–695.
26. Demer LL, Tintut Y, Parhami F. Novel mechanisms in accelerated vascular
calcification in renal disease patients. Curr Opin Nephrol Hypertens 2002;
11: 437–443.
27. Kang DH, Kanellis J, Hugo C et al. Role of the microvascular endothelium
in progressive renal disease. J Am Soc Nephrol 2002; 13: 806–816.
28. Boutouyrie P, Bussy C, Lacolley P et al. Association between local pulse
pressure, mean blood pressure, and large-artery remodeling. Circulation
1999; 100: 1387–1393.
29. Jondeau G, Boutouyrie P, Lacolley P et al. Central pulse pressure is a
major determinant of ascending aorta dilation in Marfan syndrome.
Circulation 1999; 99: 2677–2681.
30. Yamamoto Y, Sakata N, Meng J et al. Possible involvement of increased
glycoxidation and lipid peroxidation of elastin in atherogenesis in
haemodialysis patients. Nephrol Dial Transplant 2002; 17: 630–636.
31. Amann K, Wolf B, Nichols C et al. Aortic changes in experimental renal
failure: hyperplasia or hypertrophy of smooth muscle cells? Hypertension
1997; 29: 770–775.
32. Lindner A, Charra B, Sherrard DJ et al. Accelerated atherosclerosis in
prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701.
33. Zanchetti A, Bond MG, Hennig M et al. Calcium antagonist lacidipine
slows down progression of asymptomatic carotid atherosclerosis:
principal results of the European Lacidipine Study on Atherosclerosis
(ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:
2422–2427.
34. Blacher J, Safar ME, Guerin AP et al. Aortic pulse wave velocity index and
mortality in end-stage renal disease. Kidney Int 2003; 63: 1852–1860.
35. Groothoff JW, Gruppen MP, Offringa M et al. Increased arterial stiffness in
young adults with end-stage renal disease since childhood. J Am Soc
Nephrol 2002; 13: 2953–2961.
36. Guerin AP, Blacher J, Pannier B et al. Impact of aortic stiffness attenuation
on survival of patients in end-stage renal failure. Circulation 2001; 103:
987–992.
37. Mourad JJ, Girerd X, Boutouyrie P et al. Increased stiffness of radial artery
wall material in end-stage renal disease. Hypertension 1997; 30:
1425–1430.
38. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial
stiffness, and cardiovascular risk in end-stage renal disease. Hypertension
2001; 38: 938–942.
39. Haydar AA, Covic A, Colhoun H et al. Coronary artery calcification and
aortic pulse wave velocity in chronic kidney disease patients. Kidney Int
2004; 65: 1790–1794.
40. Russo D, Palmiero G, De Blasio AP et al. Coronary artery calcification in
patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44:
1024–1030.
41. Guerin AP, Blacher J, Pannier B et al. Impact of aortic stiffness attenuation
on survival of patients in end-stage renal failure. Circulation 2001; 103:
987–992.
42. Bussy C, Boutouyrie P, Lacolley P et al. Intrinsic stiffness of the carotid
arterial wall material in essential hypertensives. Hypertension 2000; 35:
1049–1054.
43. Boutouyrie P, Germain DP, Fiessinger JN et al. Increased carotid wall
stress in vascular Ehlers–Danlos syndrome. Circulation 2004; 109:
1530–1535.
44. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction
equation. Modification of Diet in Renal Disease Study Group. Ann Intern
Med 1999; 130: 461–470.
45. Froissart M, Rossert J, Jacquot C et al. Predictive performance
of the modification of diet in renal disease and Cockcroft–Gault
equations for estimating renal function. J Am Soc Nephrol 2005; 16:
763–773.
46. Rehling M, Moller ML, Thamdrup B et al. Simultaneous measurement of
renal clearance and plasma clearance of 99mTc-labelled diethylenetria-
minepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin
in man. Clin Sci (London) 1984; 66: 613–619.
47. Asmar R, Benetos A, Topouchian J et al. Assessment of arterial
distensibility by automatic pulse wave velocity measurement.
Validation and clinical application studies. Hypertension 1995;
26: 485–490.
48. Hoeks AP, Willekes C, Boutouyrie P et al. Automated detection of local
artery wall thickness based on M-line signal processing. Ultrasound Med
Biol 1997; 23: 1017–1023.
Kidney International (2006) 69, 350–357 357
M Briet et al.: Large arteries in chronic kidney disease o r i g i n a l a r t i c l e
